|
|
|
|
|
Last Trade
|
Last Trade:
$19.88
|
Change:
0.42 (2.16%)
|
Trade Time:
Jul 01
|
Market Cap:
$504.75M
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company focused on the development and
commercialization of a late-stage pipeline of novel therapies for debilitating
liver diseases. We focus on diseases for which the unmet medical need is high
and the biology for treatment is clear. Our pipeline consists of two
clinical-stage product candidates with mechanisms of action that have potential
utility across a wide range of orphan cholestatic liver diseases. We are
initially developing maralixibat for the treatment of pediatric patients with
Alagille syndrome ("ALGS") and progressive familial intrahepatic cholestasis
("PFIC"). Based on improvements in pruritus, or itching, and other outcomes and
disease markers observed in Phase 2 clinical trials, we are planning to initiate
a rolling submission of a New Drug Application ("NDA"), for the treatment of
cholestatic pruritus associated with ALGS in the third quarter of 2020.
|
|
|
|